Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICAM1 | P05362 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | SHBG | P04278 | 3/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19222394 | 0.84 | ICAM1 (0.38) | ICAM1RECQLCYP19A1ATMSHBG | |
| SCHEMBL31058464 | 0.75 | ATM (0.51) | ICAM1RECQLCYP19A1ATMSHBG | |
| SCHEMBL31005095 | 0.74 | ICAM1 (0.58) | ICAM1RECQLCYP19A1ATMALOX5 | |
| SCHEMBL31005096 | 0.74 | ICAM1 (0.58) | ICAM1RECQLCYP19A1ATMALOX5 | |
| SCHEMBL30613096 | 0.71 | CYP19A1 (0.57) | ICAM1RECQLCYP19A1ATMCYP3A4 | |
| SCHEMBL29375280 | 0.69 | ICAM1 (1.00) | ICAM1RECQLCYP19A1ATMALOX5 | |
| SCHEMBL6425405 | 0.65 | ICAM1 (0.56) | ICAM1RECQLCYP19A1ATMALOX5 | |
| SCHEMBL29886598 | 0.64 | SHBG (0.43) | CYP19A1SHBGARCYP3A4CYP1A2 | |
| SCHEMBL8571549 | 0.64 | CYP19A1 (0.30) | ICAM1RECQLCYP19A1 | |
| SCHEMBL9191205 | 0.63 | MEN1 (0.42) | ICAM1RECQLCYP19A1CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251890-B2 | Use of parthenolide derivatives as antileukemic and cytotoxic agents | UNIVERSITY OF KENTUCKY (US) | 2019-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251890-B2 | Use of parthenolide derivatives as antileukemic and cytotoxic agents | NR1H2, NR1H3, NCOR2 | ICAM1 4621/4885RECQL 3337/4885CYP19A1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.